Business Context and Reporting Period
Tenaya Therapeutics, Inc. (TNYA), a Delaware corporation, filed this Form 8-K on April 15, 2025. The report addresses a regulatory notice received from The Nasdaq Stock Market LLC regarding the continued listing of the Company's common stock on the Nasdaq Global Select Market.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on listing compliance status.
Material Changes
The Company received a notification from the Nasdaq Listing Qualifications Staff indicating non-compliance with Nasdaq Listing Rule 5450(a)(1). Specifically, the closing bid price of the Company's common stock failed to meet the minimum requirement of $1.00 per share for 30 consecutive business days between March 3, 2025, and April 12, 2025.
Outlook, Risks, and Management Commentary
- Compliance Period: The Company has been granted an initial 180-day compliance period ending October 13, 2025, to regain compliance.
- Remediation Requirements: To regain compliance, the stock must maintain a closing bid price of at least $1.00 for a minimum of ten consecutive business days during the compliance period.
- Second Compliance Period: If the Company fails to regain compliance by the initial deadline, it may be eligible for an additional 180-day period by transferring to the Nasdaq Capital Market. This requires meeting market value standards and potentially effecting a reverse stock split.
- Risks: There is no assurance the Company will be eligible for a second compliance period or that it will successfully cure the deficiency. Failure to do so could result in delisting.
- Management Action: The Company intends to actively monitor the stock price and evaluate available options to resolve the deficiency.
Investor Verification Checklist
- Verify the current closing bid price of TNYA stock to assess proximity to the $1.00 threshold.
- Monitor the Company's stock price for ten consecutive business days to determine if the initial cure requirement is met.
- Review future filings for announcements regarding a potential reverse stock split or transfer application to the Nasdaq Capital Market.
- Check for any subsequent correspondence from Nasdaq regarding the extension of the compliance period or delisting notices.